---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-26-000005"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2026-01-28T23:59:59+00:00"
generated_at: "2026-05-16T07:02:36.415961+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics receives FDA clearance for SER-252 IND in advanced Parkinson's

## Summary
- FDA cleared IND for SER-252, an investigational therapy for advanced Parkinson's disease.
- Phase 1b registrational study to start; site and regulatory activities in Australia underway.
- FDA alignment on 505(b)(2) NDA pathway provides clear development path for SER-252.
- CEO Steve Ledger calls milestone a major step toward addressing significant unmet need.

## SEC filing metadata
- accession: 0001708599-26-000005
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2026-01-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000005/0001708599-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000005/ser-20260127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-26-000005
- JSON: https://secwatch.observer/filing/0001708599-26-000005.json
- Plain text: https://secwatch.observer/filing/0001708599-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.